First-in-Human Use of CereVasc® eShunt® System in Idiopathic Intracranial Hypertension Demonstrates Sustained Clinical Outcomes

First-in-Human Use of CereVasc® eShunt® System in Idiopathic Intracranial Hypertension Demonstrates Sustained Clinical Outcomes Compassionate Use Case Reports Continued Symptom Improvement and Imaging-Confirmed Device Patency Through Three-Year Follow-Up BOSTON, March 4, 2026 – CereVasc, Inc., a clinical-stage medical device company developing novel minimally invasive treatments for neurological diseases, today announced the publication of a […] The post First-in-Human Use of CereVasc® eShunt® System in Idiopathic Intracranial Hypertension Demonstrates Sustained Clinical Outcomes appeared fi